Current issues in the pharmacologic management of obsessive compulsive disorder.
In spite of significant advances in the development of behavioral and pharmacologic strategies for the treatment of obsessive compulsive disorder, little is known about the comparative efficacy and safety of those treatments. In addition, questions about the dose and duration in maintenance treatment remain unknown. This article reviews current issues in the pharmacologic management of patients with obsessive compulsive disorder.
Rasmussen
S A
SA
Department of Psychiatry and Human Behavior, Brown University, Providence, R.I. 02906.
Eisen
J L
JL
Pato
M T
MT
D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001521:Behavior Therapy; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D015337:Multicenter Studies as Topic; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors